ARCHIVES

FDA News:: ODAC Commends Ciba For Design Of Trials Legal Issues:

This article is from The Cancer Letter archive.

Vol. 23 No. 01 | January 10, 1997

Download PDF Visit The Full Archive

Related Articles

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

Nexavar Improves PFS In Phase III Trial

January 25, 2013

NCI Seen Shifting Away From Comprehensive Center Emphasis Toward Encouraging Clinical Excellence

April 30, 1976

Small But Valued NIH Grant Program Cut In FY92 Budget

April 12, 1991

Nevins Reverses Position, Claims Potti Manipulated Data For Basis of Clinical Trials

February 17, 2012

Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone

February 25, 2011